Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

Rudolfová, Petra; Hanušová, Veronika; Skálová, Lenka; Bártíková, Hana; Matoušková, Petra; Boušová, Iva

doi:10.2478/acph-2014-0018

Abstract

Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied in HCT-8 cancer cells. Rat hepatocytes were used to study the influence of EGCG on DOX hepatotoxicity. Cell proliferation and viability were studied by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide and neutral red uptake test assays. Formation of reactive oxygen species (ROS) was determined using the dichlorofluorescein assay. All of the studied catechins (1-25 μmol L^-1) had no effect on the proliferation of intestinal cancer cells and did not affect the antiproliferative effect of DOX (1-8 μmol L^-1) in these cells. Moreover, EGCG at 25 μmol L^-1 increased the viability of isolated hepatocytes and significantly protected these cells against DOX-induced toxicity and ROS production. Consumption of EGCG during DOX therapy seems to be safe and beneficial, since EGCG does not decrease DOX anticancer efficacy and could ameliorate DOX hepatotoxicity

References

1. R. Ng, N. Better and M. Green, Anticancer agents and cardiotoxicity, Semin. Oncol. 33 (2006) 2-14; DOI: 10.1053/j.seminoncol.2005.11.001.10.1053/j.seminoncol.2005.11.001
Search in Google Scholar
2. K. Schimmel, D. Richel, R. van den Brink and H. J. Guchelaar, Cardiotoxicity of cytotoxic drugs, Cancer Treat. Rev. 30 (2004) 181-191; DOI: 10.1016/j.ctrv.2003.07.003.10.1016/j.ctrv.2003.07.003
Search in Google Scholar
3. T. Simunek, M. Sterba, O. Popelova, M. Adamcová, R. Hrdina and V. Gersl, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol. Rep. 61 (2009) 154-171.
Search in Google Scholar
4. S. Kalender, Y. Kalender, A. Ates, M. Yel, E. Olcay and S. Candan, Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats, Braz. J. Med. Biol. Res. 35 (2002) 1379-1387; DOI: 10.1590/s0100-879x2002001100017.10.1590/S0100-879X2002001100017
Search in Google Scholar
5. Y. Kalender, M. Yel and S. Kalender, Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats - the effects of vitamin E and catechin, Toxicology 209 (2005) 39-45; DOI: 10.1016/j.tox.2004.12.003.10.1016/j.tox.2004.12.003
Search in Google Scholar
6. J. H. Doroshow, Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents, Biochem. Biophys. Res. Commun. 135 (1986) 330-335; DOI: 10.1016/0006-291x(86)90981-2.10.1016/0006-291X(86)90981-2
Search in Google Scholar
7. B. K. Sinha, A. G. Katki, G. Batist, K. H. Cowan and C. E. Myers, Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells, Biochem. Pharmacol. 36 (1987) 793-796; DOI: 10.1016/0006-2952(87)90164-x.10.1016/0006-2952(87)90164-X
Search in Google Scholar
8. A. L. A. Ferreira, L. S. Matsubara andB. B. Matsubara, Anthracycline-induced cardiotoxicity, Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 278-281; DOI: 10.2174/187152508785909474.10.2174/18715250878590947418855640
Search in Google Scholar
9. C. Carvalho, R. X. Santos, S. Cardoso, S. Correia, P. J. Oliveira, M. S. Santos and P. I. Moreira, Doxorubicin: the good, the bad and the ugly effect, Curr. Med. Chem. 16 (2009) 3267-3285; DOI: 10.2174/092986709788803312.10.2174/09298670978880331219548866
Search in Google Scholar
10. Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield and D. K. St Clair, Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues, Mol. Interv. 7 (2007) 147-156; DOI: 10.1124/mi.7.3.6.10.1124/mi.7.3.617609521
Search in Google Scholar
11. A. Mohan, S. Narayanan, S. Sethuraman and U. M. Krishnan, Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy, Anti-Cancer Agents Med. Chem. 13 (2013) 281-295; DOI: 10.2174/1871520611313020015.10.2174/187152061131302001522721388
Search in Google Scholar
12. V. Hanušová, I. Boušová and L. Skálová, Possibilities to increase the effectiveness of doxorubicin in cancer cells killing, Drug Metab. Rev. 43 (2011) 540-557; DOI: 10.3109/03602532.2011. 609174.
Search in Google Scholar
13. H. K. Biesalski and J. Frank, Antioxidants in cancer therapy: is there a rationale to recommend antioxidants during cancer therapy? Biofactors 17 (2003) 229-240; DOI: 10.1002/biof.5520170122.10.1002/biof.552017012212897444
Search in Google Scholar
14. K. A. Conklin, Cancer chemotherapy and antioxidants, J. Nutr. 134 (2004) 3201S-3204S.
Search in Google Scholar
15. D. Procházková, I. Boušová and N. Wilhelmová, Antioxidant and prooxidant properties of flavonoids, Fitoterapia 82 (2011) 513-523; DOI: 10.1016/j.fitote.2011.01.018.10.1016/j.fitote.2011.01.01821277359
Search in Google Scholar
16. L. Patil and R. Balaraman, Effect of green tea extract on doxorubicin induced cardiovascular abnormalities: antioxidant action, Iran. J. Pharm. Res. 10 (2011) 89-96.
Search in Google Scholar
17. Y. Du and H. X. Lou, Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin- -induced toxicity in cardiomyocytes, Eur. J. Pharmacol. 591 (2008) 96-101; DOI: 10.1016/j.ejphar. 2008.06.068.
Search in Google Scholar
18. J. Zheng, H. C. M. Lee, M. M. bin Sattar, Y. Huang and J. S. Bian, Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury, Eur. J. Pharmacol. 652 (2011) 82-88; DOI: 10.1016/j.ejphar.2010.10.082.10.1016/j.ejphar.2010.10.08221114975
Search in Google Scholar
19. R. H. Mohamed, R. A. Karam and M. G. Amer, Epicatechin attenuates doxorubicin-induced brain toxicity: critical role of TNF-alpha, iNOS and NF-kappa B, Brain Res. Bull. 86 (2011) 22-28; DOI: 10.1016/j.brainresbull.2011.07.001.10.1016/j.brainresbull.2011.07.00121763406
Search in Google Scholar
20. K. Sato, K. Sueoka, R. Tanigaki, H. Tajima, A. Nakabayashi, Y. Yoshimura and Y. Hosoim, Green tea extracts attenuate doxorubicin-induced spermatogenic disorders in conjunction with higher telomerase activity in mice, J. Assist. Reprod. Genet. 27 (2010) 501-508; DOI: 10.1007/s10815-010- -9438-z.
Search in Google Scholar
21. N. Kassner, K. Huse, H. J. Martin, U. Gödtel-Armbrust, A. Metzger, I. Meineke, J. Brockmöller, K. Klein, U. M. Zanger, E. Maser and L. Wojnowski, Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver, Drug Metab. Dispos. 36 (2008) 2113-2120; DOI: 10.1124/dmd.108.022251.10.1124/dmd.108.02225118635746
Search in Google Scholar
22. W. X. Huang, L. Y. Ding, Q. A. Huang, H. Hu, S. Liu, X. Yang, X. Hu, Y. Dang, S. Shen, J. Li, X. Ji, S. Jiang, J. O. Liu and L. Yu, Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma, Hepatology 52 (2010) 703-714; DOI: 10.1002/hep.23723.10.1002/hep.2372320683966
Search in Google Scholar
23. M. N. Berry, A. Edwards and G. Barritt, Isolated Hepatocytes: Preparation, Properties and Applications, Elsevier Science Publishers, Amsterdam 1991, pp. 15-58.
Search in Google Scholar
24. H. Wang and J. A. Joseph, Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader, Free Rad. Biol. Med. 27 (1999) 612-616; DOI: 10.1016/s0891-5849(99) 00107-0.
Search in Google Scholar
25. N. P. Seeram, Y. J. Zhang and M. G. Nair, Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins, Nutr. Cancer 46 (2003) 101-106; DOI: 10.1207/s15327914nc4601_13.10.1207/S15327914NC4601_1312925310
Search in Google Scholar
26. G. Liang, A. Z. Tang, X. Z. Lin, L. Li, S. Zhang, Z. Huang, H. Tang and Q. Q. Li, Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer, Int. J. Oncol. 37 (2010) 111-123; DOI: 10.3892/ijo_00000659.10.3892/ijo_00000659
Search in Google Scholar
27. G. W. Dryden, A. Lam, K. Beatty, H. H. Qazzaz and C. J. McClain, A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis, Inflamm. Bowel Dis. 19 (2013) 1904-1912; DOI: 10.1097/MIB.0b013e31828f5198.10.1097/MIB.0b013e31828f519823846486
Search in Google Scholar
28. H. H. Chow, I. A. Hakim, D. R. Vining, J. A. Crowell, J. Ranger-Moore, W. M. Chew, C. A. Celaya, S. R. Rodney, Y. Hara and D. S. Alberts, Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals, Clin. Cancer Res. 11 (2005) 4627-4633; DOI: 10.1158/1078-0432.CCR-04-2549.10.1158/1078-0432.CCR-04-254915958649
Search in Google Scholar
29. G. Stammler and M. Volm, Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines, Anti-cancer Drugs 8 (1997) 265-268.10.1097/00001813-199703000-000079095331
Search in Google Scholar
30. G. Mazzanti, F. Menniti-Ippolito, P. A. Moro, F. Cassetti, R. Raschetti, C. Santuccio and S. Mastrangelo, Hepatotoxicity from green tea: a review of the literature and two unpublished cases, Eur. J. Clin. Pharmacol. 65 (2009) 331-341; DOI: 10.1007/s00228-008-0610-7 10.1007/s00228-008-0610-719198822
Search in Google Scholar

Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

Abstract

Paradigm

My account